Compare NVNI & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVNI | BNGO |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.5M |
| IPO Year | 2023 | 2018 |
| Metric | NVNI | BNGO |
|---|---|---|
| Price | $0.94 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.1K | ★ 2.5M |
| Earning Date | 09-21-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | $0.05 | $12.73 |
| Revenue Next Year | $10.26 | $34.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.31 | $1.00 |
| 52 Week High | $4.94 | $2.23 |
| Indicator | NVNI | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 57.10 |
| Support Level | $0.78 | $1.10 |
| Resistance Level | $1.28 | $1.68 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 39.78 | 37.94 |
Nvni Group Ltd, through its existing subsidiary companies, operates business-to-business software-as-a-service (B2B SaaS) products in Brazil, serving a diversified customer base of small and mid-sized enterprises across vertical markets. The Group's core business activity is providing a SaaS platform model focused on the software delivery method of cloud-based software applications to its customers. The Group generates revenues and profits from SaaS platform subscription services, data analytics services, set-up and other services. The Group has a single operating and reportable segment, multi-vertical SaaS solution model. The Group operates and generates revenue from Brazil.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.